FDA hearing on Amgen's Tavneos will include findings from an independent review

An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare disease treatment remain | An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare disease treatment remains on the market.